Tags

Type your tag names separated by a space and hit enter

Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season.
Euro Surveill. 2019 Aug; 24(31)ES

Abstract

IntroductionInfluenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition.AimTo estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored.MethodsThis was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries.ResultsOverall, 2017/18 IVE was 9.9% (95% CI: -15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), -29.9% (95% CI: -79.1% to 5.8%) and 25.7% (95% CI: -8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: -24.4% to 34.9%) and 7.8% (95% CI: -23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%).ConclusionOur data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage.

Authors+Show Affiliations

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain.Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain.Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain.Hospital Doctor Peset, Valencia, Spain.Hospital Universitario y Politécnico La Fe, Valencia, Spain.Universidad CEU Cardenal Herrera, Castellón, Spain. Hospital General Universitario de Castellón, Castellón, Spain.Hospital General de Alicante, Alicante, Spain.Centro de Salud Pública de Castellón, Castellón, Spain. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain.Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain.The Network members are acknowledged at the end of the article.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

31387672

Citation

Mira-Iglesias, Ainara, et al. "Influenza Vaccine Effectiveness Against Laboratory-confirmed Influenza in Hospitalised Adults Aged 60 Years or Older, Valencia Region, Spain, 2017/18 Influenza Season." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 24, no. 31, 2019.
Mira-Iglesias A, López-Labrador FX, Baselga-Moreno V, et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Euro Surveill. 2019;24(31).
Mira-Iglesias, A., López-Labrador, F. X., Baselga-Moreno, V., Tortajada-Girbés, M., Mollar-Maseres, J., Carballido-Fernández, M., Schwarz-Chavarri, G., Puig-Barberà, J., Díez-Domingo, J., & On Behalf Of The Valencia Hospital Network For The Study Of Influenza And Respiratory Viruses Disease, . (2019). Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 24(31). https://doi.org/10.2807/1560-7917.ES.2019.24.31.1800461
Mira-Iglesias A, et al. Influenza Vaccine Effectiveness Against Laboratory-confirmed Influenza in Hospitalised Adults Aged 60 Years or Older, Valencia Region, Spain, 2017/18 Influenza Season. Euro Surveill. 2019;24(31) PubMed PMID: 31387672.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. AU - Mira-Iglesias,Ainara, AU - López-Labrador,F Xavier, AU - Baselga-Moreno,Víctor, AU - Tortajada-Girbés,Miguel, AU - Mollar-Maseres,Juan, AU - Carballido-Fernández,Mario, AU - Schwarz-Chavarri,Germán, AU - Puig-Barberà,Joan, AU - Díez-Domingo,Javier, AU - On Behalf Of The Valencia Hospital Network For The Study Of Influenza And Respiratory Viruses Disease,, PY - 2019/8/8/entrez PY - 2019/8/8/pubmed PY - 2020/7/18/medline KW - Spain KW - epidemiology KW - hospitalisations KW - influenza KW - influenza virus KW - surveillance KW - vaccine KW - viral infections JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 24 IS - 31 N2 - IntroductionInfluenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition.AimTo estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored.MethodsThis was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries.ResultsOverall, 2017/18 IVE was 9.9% (95% CI: -15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), -29.9% (95% CI: -79.1% to 5.8%) and 25.7% (95% CI: -8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: -24.4% to 34.9%) and 7.8% (95% CI: -23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%).ConclusionOur data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/31387672/Influenza_vaccine_effectiveness_against_laboratory_confirmed_influenza_in_hospitalised_adults_aged_60_years_or_older_Valencia_Region_Spain_2017/18_influenza_season_ L2 - http://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.31.1800461 DB - PRIME DP - Unbound Medicine ER -